Galectin Therapeutic GALT

$GALT short term trend lines (orange) meet Friday, October 9th...doubt we get news this week and break out of this wedge honestly, hoping for it though. Mid term trend lines (blue) meet Tuesday, November 17th...down to $3.20's possible Worst case scenarios: Yearly support line, down to $2.30's possible Multi DECADE support line (shown on second chart, goes back to 2008), down to $0.80's possible GLTA

$GALT AASLD The Liver Meeting: Typically held in early November (e.g., November 7–11). Abstracts for late-breaking data at AASLD are commonly released online roughly 21 days prior to the conference kickoff.

$GALT Now i need the shorts to show some CONVICTION and drive the orice way down one mire time (despite my prefiction below) I Want To RELOAD!!!

$GALT I’m expecting a big selloff of borrowed shares by shorts on Monday. Because the company has shown its hand by asking to authorise new shares. They’ll partner but only if the price is right. The extra shares tell their partner/ buyer that they can always fund this themselves. So what are shorts to do? Not easy to cover 9 million shares sold short. To do it without starting margin calls is impossible. So all they have left is psychops by throwing more borrowed shares at the market. They will provide the cheapest shares in quite some time. Watch it open lower and drop down until the tutes decide it’s cheap enough and they restart their quiet accumulation. Cheaper to do thanks to those loser shorts. We’ve seen it too many times in the last weeks but Monday will be the red line for shorts. They can only sacrifice more borrowed shares and hope to put margin calls off for another day. First ones out suffer least. Anyone lending their shares right now is a traitor.

$GALT so where does this leave shorts ?

$GALT Expanding the share pool gives them the leverage to secure partnerships, satisfy institutional investors, or execute secondary offerings to prove they can sustain operations through regulatory review Good News , buy more stock its going to happen

$GALT Galectin Therapeutics Inc. has registered or authorized those additional shares to provide financial flexibility for future needs, which is a standard regulatory practice for clinical-stage biotechnology companies. When a company states they have "no current plan" for newly authorized or shelf-registered shares, it means there is no immediate, legally binding agreement to issue them tomorrow. However, they structure it this way for specific strategic reasons: • Strategic Partnerships: Galectin has publicly stated that it is actively exploring strategic and financial partnership opportunities to support the development and commercialization of its Phase 3 drug, belapectin. Having pre-authorized shares allows them to move quickly if a big pharma partner wants to buy a stake in the company. No what you own just let this game play out Good Luck to all Longs.